36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
1 citations
,
August 2024 in “Indian Dermatology Online Journal” Bicalutamide may effectively treat female pattern hair loss with minimal side effects.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
3 citations
,
October 2018 in “Journal of cosmetic dermatology” Pentoxifylline alone and combined with triamcinolone acetonide is effective for treating localized alopecia areata, with the combination showing the highest effectiveness.
June 2024 in “Advances in therapy” IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
November 2025 in “International Journal Of Ayurvedic And Herbal Medicine” A multidisciplinary approach effectively improves trichotillomania without side effects.
September 2015 in “American journal of biomedicine” 22 citations
,
January 1992 in “PubMed” Higher CSF 5-HIAA levels may predict better response to serotonin re-uptake inhibitors in trichotillomania.
May 2008 in “Trends in Urology Gynaecology & Sexual Health” Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
16 citations
,
November 2018 in “Medicinal Chemistry” The compound GD-23 may reduce anxiety like diazepam by targeting the TSPO receptor.
April 2016 in “Apollo (University of Cambridge)” Trichotillomania is a hair-pulling disorder needing different treatments than OCD.
24 citations
,
January 2017 in “International Journal of Trichology”
8 citations
,
September 2021 in “Skin appendage disorders” Trichotillomania treatment is most successful with a mix of behavioral therapy, medication, and social support.
7 citations
,
October 2017 in “Behavioural Pharmacology” Fluoxetine's effectiveness as an antidepressant in mice depends on a specific protein activity and a 5-minute pretest.
29 citations
,
October 2020 in “Environmental health perspectives” Five preservatives may disrupt hormone function and need more health and environmental risk assessment.
Trichotillomania treatment is improving with behavior therapy and new drug approaches, but challenges like stigma and underdiagnosis remain.
29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
20 citations
,
January 2017 in “Actas Dermo-Sifiliográficas” Recent advances in hair loss treatments show significant progress.
8 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Bicalutamide may be a promising alternative treatment for female pattern hair loss.
November 2024 in “Cureus” Combining therapy, behavior techniques, and medication can help manage trichotillomania and depression.
July 1993 in “Inpharma Weekly” Dicentrine reduced heart disease risk factors in rats, T-588 protected mice brains without side effects, Provir blocked herpes virus and lessened mouse symptoms, and LY191704 could treat hair loss and prostate issues.
75 citations
,
September 1971 in “British Journal of Dermatology” Both steroids effectively promote hair growth for at least 9 months.